^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LY3076226

    i
    Other names: LY3076226, LY-3076226, LY 3076226
    Company:
    AbbVie, Eli Lilly
    Drug class:
    Microtubule inhibitor, FGFR3-targeted antibody-drug conjugate
    Related drugs:
    almost3years
    A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer. (PubMed, Invest New Drugs)
    Dose escalation of LY3076226 beyond 5.0 mg/kg in patients with advanced tumors may be possible. The trial was registered on August 19, 2015 under identifier NCT02529553 with ClinicalTrials.gov.
    Clinical • P1 data • Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    LY3076226